In combination with chemoRT, several drugs, including Cilengitide (αvβ3/αvβ5-integrin inhibitor), Nivolumab (anti-PD-1 antibody), and Bevacizumab (BVZ, anti-VEGF antibody), failed to enhance OS in phase III trials for newly diagnosed GBM [61], though retrospective analysis suggests BVZ may benefit Proneural GBM patients [61]. Here, VEGFA is linked to glioblastoma.